Start here if you're new
what it is
Context Therapeutics is building cancer drugs that try to direct your immune cells toward solid tumors.
how it gets paid
Last year Context Therapeutics made n/a in revenue. CTIM-76 program-related revenue was the main engine at $0.8M, or 27% of sales.
what just happened
Latest quarter revenue was $2M, but CNTX still lost $0.24 per share.
At a glance
C++ balance sheet — some cracks in the foundation
-$0.46 fy2024 eps est
$3M fy2024 rev est
1.3 beta
~$309M market cap
xvary composite: 41/100 — below average
What they do
Context Therapeutics is building cancer drugs that try to direct your immune cells toward solid tumors.
The edge here is focus, not scale. T cell engager (a drug that pulls immune cells toward cancer) → plain English: a guided missile for T cells → so what: one good signal can reprice a tiny company fast. With just 12 employees and three named programs, you are buying concentrated shots on goal, not a sprawling drug empire.
How they make money
n/a
annual revenue
CTIM-76 program-related revenue
$0.8M
flat
CT-95 program-related revenue
$0.8M
flat
CT-202 program-related revenue
$0.7M
flat
Other collaboration and research revenue
$0.7M
up
The products that matter
preclinical and clinical oncology pipeline
T Cell Engager Pipeline
$3M revenue · no approved products
this is effectively the whole story. the company has only $3M in annual revenue, so almost all of the $309M market value is tied to whether its experimental cancer programs become clinically interesting.
pipeline only
Key numbers
$3M
2024 revenue est
Estimated 2024 revenue is just $3 million. So what: against a roughly $309 million market cap, you are paying about 103 times sales for a clinical story.
12
employees
Twelve employees for a $309M company tells you this is a lean biotech shell around a few core assets, not an operating machine.
-$0.46
2024 EPS est
Losses are narrowing from -$1.50 in 2023 to -$0.46 in 2024. Better is not profitable.
1.3
beta
Beta 1.3 means the stock tends to swing more than the market. In biotech, that usually feels even larger.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CNTX right now.
source: institutional data · return history unavailable
What just happened
reported a loss
Latest quarter revenue was $2M, but CNTX still lost $0.24 per share.
Revenue rose 80% vs. prior year from a tiny base, while EPS was -$0.24 — vs. prior year % is misleading across the zero line; confirm both quarters in the filing. Quiet part out loud: the income statement is still a placeholder for trial updates.
$2M
revenue
-$0.24
eps
+80%
revenue vs. last year
the number that mattered
$2M matters because it is two-thirds of the full-year $3M revenue estimate, which shows how thin and lumpy this business still is.
source: EDGAR filing data, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is clinical disappointment before the pipeline becomes commercially relevant. CNTX has only $3M in annual revenue, so there is very little operating business underneath the science.
med
Binary trial economics
There are no approved products to offset a setback. If the core T cell engager programs fail to produce convincing data, the company has very little else for investors to lean on.
impact: with a $309M market cap and no meaningful commercial base, bad data would pressure the whole equity story at once.
med
Cash burn and future dilution
CNTX has $76.94M in cash and only $3M in annual revenue. That means operations are still funded mainly by capital already raised, not by the business paying for itself.
impact: if clinical timelines slip or spending rises, new equity issuance becomes the obvious tool — and your ownership percentage usually shrinks when that happens.
med
Extreme stock volatility
Price stability is 5 / 100 and beta is 1.3. This is already a volatile stock before you add the normal biotech headline cycle on top.
impact: even small disappointments can hit a name like this harder because there is not much fundamental ballast under the share price.
A forced reset in expectations would hit both sides of the story: the pipeline narrative and the financing runway that supports it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next clinical update
This stock needs proof, not promises. Any disclosed trial timing or data milestone matters more than another quarter of small reported revenue.
metric
cash versus the current $76.94M base
Cash is the key operating metric here. If it moves down quickly without a corresponding step forward in the pipeline, financing risk rises.
risk
dilution signals in filings and updates
A pre-commercial biotech with $3M in revenue does not have many funding options. You want to know early if management starts leaning on the equity market again.
trend
whether losses deepen beyond the recent -$0.10 quarter
One quarter does not decide the story, but a worsening loss profile without visible pipeline progress would make the $309M valuation harder to defend.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for CNTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive